CVC  Alexandria Venture Investments

http://www.are.com/





     Office Locations:

400 Technology Square, Suite 101
Cambridge, MA 02139
Phone: 508-755-4249

Get all office locations for this firm with a National Database subscription or New York Database subscription.
 

Stages:

  • Early
  • Seed


 

Industries:

  • Energy & Clean Tech
  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Alexandria Venture Investments is the strategic investment entity of Alexandria Real Estate Equities, Inc. (ARE: NYSE). Alexandria Equities provides capital to the broad and diverse life science sector. Since 1994, Alexandria Real Estate has created first-in-class life science clusters that foster innovative and collaborative environments in key locations immediately proximate to leading research institutions. Alexandria's diverse tenant base includes internationally renowned academic and medical institutions, multinational pharmaceutical companies, leading private and public biotechnology entities, non-profit institutions, government agencies, medical device companies, biofuels companies, research tools and service companies, and venture capitalists.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Amanda Cashin PhD Senior Vice President
    Andres Gavinet Chief Accounting Officer
    Daniel J. Ryan Executive VP and Regional Market Director
    Dean A. Shigenaga Chief Financial Officer & Treasurer
    Jennifer J. Banks Executive Vice President

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      11/08/2021


      GeneCentric Therapeutics


      NC


      $7,500,000


      Series B-1


      11/06/2021


      Parthenon Therapeutics


      MA


      $65,000,000


      Series A


      10/27/2021


      Mozart Therapeutics


      WA


      $55,000,000


      Series A


      09/03/2021


      Disc Medicine


      MA


      $90,000,000


      Series B


      08/18/2021


      Immunitas Therapeutics


      MA


      $58,000,000


      Series B


      08/03/2021


      SeQure Dx


      MA


      $17,500,000


      Series A


      07/14/2021


      AXONIS Therapeutics


      MA


      $5,000,000


      


      06/23/2021


      ImmuneID


      MA


      $50,000,000


      Series A


      06/22/2021


      Neurona Therapeutics


      CA


      $41,500,000


      Venture


      05/27/2021


      miRecule


      MD


      $5,700,000


      Seed


      05/12/2021


      Inari


      MA


      $208,000,000


      Series D


      05/07/2021


      TwinStrand Biosciences


      WA


      $50,000,000


      Series B


      04/15/2021


      Molecular Assemblies


      CA


      $24,000,000


      Series A


      04/02/2021


      Alloy Therapeutics


      MA


      $75,000,000


      Series C


      03/16/2021


      StrideBio


      NC


      $81,500,000


      Series B


      03/15/2021


      Insitro


      CA


      $400,000,000


      Series C


      02/12/2021


      Ensoma


      MA


      $70,000,000


      Series A


      01/22/2021


      Vera Therapeutics


      CA


      $80,000,000


      Series C


      01/15/2021


      AltPep


      WA


      $23,150,000


      Series A


      01/08/2021


      DiCE Molecules


      CA


      $80,000,000


      Series C


      01/08/2021


      Blacksmith Medicines


      CA


      undisclosed


      Seed


      12/16/2020


      Neurogene


      NY


      $115,000,000


      Series B


     

    Portfolio companies include:


      Adaptive Phage Therapeutics
        web link


      Affinia Therapeutics
        web link


      Alloy Therapeutics
        web link


      AltPep
        web link


      Arrakis Therapeutics
        web link


      Aura Biosciences
        web link


      Avelas Biosciences
        web link


      Avidity Biosciences
        web link


      AXONIS Therapeutics
        web link


      Benson Hill Biosystems
        web link


      Blacksmith Medicines
        web link


      BlackThorn Therapeutics
        web link


      Boragen


      Boundless Bio
        web link


      Cardea Bio
        web link


      Cibus
        web link


      Compass Therapeutics
        web link


      Crop Enhancement


      Cydan
        web link


      DiCE Molecules
        web link


      Disc Medicine
        web link


      Dren Bio
        web link


      Ensoma
        web link


      EpiBiome
        web link


      GeneCentric Therapeutics
        web link


      GNS Healthcare
        web link


      Greenlight Biosciences


      Gritstone Oncology
        web link


      Homology Medicines
        web link


      Imara
        web link


      ImmuneID
        web link


      Immunitas Therapeutics
        web link


      Immusoft


      Inari
        web link


      Insitro
        web link


      Jasper Therapeutics
        web link


      Kallyope
        web link


      Karuna Pharmaceuticals
        web link


      Maze Therapeutics


      Metacrine
        web link


      miRecule
        web link


      Molecular Assemblies
        web link


      MouSensor
        web link


      Mozart Therapeutics
        web link


      Neurogene
        web link


      Neurona Therapeutics
        web link


      Nitrome Biosciences
        web link


      OncoResponse
        web link


      ORIG3N
        web link


      Parthenon Therapeutics
        web link


      Prevail Therapeutics
        web link


      Redpin Therapeutics
        web link


      Relay Therapeutics
        web link


      RGenix
        web link


      Ribometrix
        web link


      SeQure Dx
        web link


      Silverback Therapeutics
        web link


      Sonoma Biotherapeutics
        web link


      Stoke Therapeutics
        web link


      Strand Therapeutics
        web link


      StrideBio
        web link


      TARA Biosystems
        web link


      Tiburio Therapeutics
        web link


      TwinStrand Biosciences
        web link


      Ubiq Security
        web link


      Vera Therapeutics
        web link


      Verseau
        web link


      Visterra
        web link


      Vividion Therapeutics
        web link


      Vor Biopharma
        web link


      X-Vax Technology
        web link


     

    Recent News: